Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial Analysis & Valuation | Quarter Chart
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
CTNMPrice: $13.28
Fair Value: 🔒
🔒score
Description
Shares
| Market Cap | $495.82M | Exchange | NASDAQ |
| Sector | — | Industry | — |
| Country | — | CEO | Carmine N. Stengone |
| IPO Date | 2024-04-05 | CAGR | — |
| Employees | 41 | Website | — |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CTNM chart loading...
Fundamentals
Technicals
| Enterprise Value | $242.80M | P/E Ratio | -6.12 |
| Forward P/E | -5.89 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.66 |
| P/CF Ratio | -3.16 | P/FCF Ratio | -4.09 |
| EPS | $-2.17 | EPS Growth 1Y | 68.35% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.3% | ROA | -0.21% |
| ROCE | 0.13% | Current Ratio | 27.5 |
| Quick Ratio | 27.5 | Cash Ratio | 7.76 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | 18.4 | Piotroski Score | 2 |
View Contineum Therapeutics, Inc. Class A Common Stock financial charts →